Active Comparator-Controlled Study to Assess Safety and Efficacy of ISIS-FXIRx in Total Knee Arthroplasty

PHASE2CompletedINTERVENTIONAL
Enrollment

315

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

May 31, 2014

Study Completion Date

August 31, 2014

Conditions
Venous Thromboembolism
Interventions
DRUG

ISIS-FXIRx Dose #2

Group B: ISIS-FXIRx dose #2 subcutaneously administered 7 times prior to total knee arthroplasty, and 2 times after surgery.

DRUG

ISIS-FXIRx Dose #3

Group C: ISIS-FXIRx dose #3 subcutaneously administered 7 times prior to total knee arthroplasty, and 2 times after surgery.

DRUG

Enoxaparin

Enoxaparin (40mg) will be administered by subcutaneous injection the evening prior to total knee arthroplasty (optionally), 6 to 8 hours after surgery, followed by daily injections for at least 8 additional days post surgery (a total of at least 9 consecutive days). \[Except for Canadian region, in which the subcutaneous injection of enoxaparin the evening prior to total knee arthroplasty is expected, resulting in a total of at least 10 consecutive days of enoxaparin.\]

Trial Locations (21)

1527

Isis Investigational Site, Sofia

4002

Isis Investigational Site, Plovdiv

7002

Isis Investigational Site, Rousse

18009

Isis Investigational Site, Cherkassy

61024

Isis Investigational Site, Kharkiv

65025

Isis Investigational Site, Odesa

76000

Isis Investigational Site, Ivano-Frankivsk

99018

Isis Investigational Site, Sevastopol

150047

Isis Investigational Site, Yaroslavl

193312

Isis Investigational Site, Saint Petersburg

194291

Isis Investigational Site, Saint Petersburg

194354

Isis Investigational Site, Saint Petersburg

443095

Isis Investigational Site, Samara

454026

Isis Investigational Site, Chelyabinsk

460000

Isis Investigational Site, Orenburg

LIS 2J4

Isis Investigational Site, Ajax

LIG 2B9

Isis Investigational Site, Oshawa

LV 2164

Isis Investigational Site, Ādaži

LV 1004

Isis Investigational Site, Riga

LV4201

Isis Investigational Site, Valmiera

01107

Isis Investigational Site, Kyiv

Sponsors
All Listed Sponsors
lead

Ionis Pharmaceuticals, Inc.

INDUSTRY